Literature DB >> 16082506

Effects of anaesthetics on the loss of nigrostriatal dopaminergic neurons by 6-hydroxydopamine in rats.

K P Datla1, V Zbarsky, D T Dexter.   

Abstract

Various studies use ketamine/xylazine, fentanyl/medetomidine, etorphine/methotrimeprazine, and isoflurane anaesthesia for creating the 6-hydroxydopamine (6-OHDA)-lesion rat model of Parkinson's disease. As these anaesthetics are known to modulate uptake and turnover of dopamine and that 6-OHDA-induced neurotoxicity is also dependents on uptake/turnover, we studied the effects of these anaesthetics on the extent of nigrostriatal dopaminergic damage caused by 6-OHDA. Infusion of 8 microg of 6-OHDA into the medial forebrain bundle significantly reduced the numbers of dopaminergic cells in nigra and striatal concentrations of dopamine in animals anaesthetized with fentanyl/medetomidine, etorphine/methotrimeprazine and isoflurane but not with ketamine/xylazine. In the latter group, however, increasing the dose of 6-OHDA to 10 and 12 microg resulted in a moderate (15 and 29%), but significant loss of dopaminergic cells. A severe loss of dopaminergic cells (59% and 81%) was seen with these doses in isoflurane-anaesthetized animals, but with only 8 microg in etorphine/methotrimeprazine-anaesthetized animals. Thus, these results suggest that the extent of nigrostriatal dopaminergic neuronal loss with 6-OHDA seems to be influenced by anaesthetic used during the surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082506     DOI: 10.1007/s00702-005-0353-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.850


  28 in total

1.  Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain.

Authors:  H Tsukada; S Nishiyama; T Kakiuchi; H Ohba; K Sato; N Harada; S Nakanishi
Journal:  Brain Res       Date:  1999-12-04       Impact factor: 3.252

2.  Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine.

Authors:  Y Glinka; K F Tipton; M B Youdim
Journal:  J Neurochem       Date:  1996-05       Impact factor: 5.372

3.  Fentanyl increases dopamine release in rat nucleus accumbens: involvement of mesolimbic mu- and delta-2-opioid receptors.

Authors:  Y Yoshida; S Koide; N Hirose; K Takada; K Tomiyama; N Koshikawa; A R Cools
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

4.  Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.

Authors:  K P Datla; S B Blunt; D T Dexter
Journal:  Mov Disord       Date:  2001-05       Impact factor: 10.338

5.  Ketamine stereoselectively inhibits rat dopamine transporter.

Authors:  M Nishimura; K Sato
Journal:  Neurosci Lett       Date:  1999-10-22       Impact factor: 3.046

6.  The effects of etorphine, fentanyl and morphine on noradrenaline and dopamine concentrations in the striatum of rat.

Authors:  J K Teuchmann; B F Kania
Journal:  Acta Physiol Pol       Date:  1977 Mar-Apr

7.  6-hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: implication of peroxynitrite formation.

Authors:  B Ferger; C Themann; S Rose; B Halliwell; P Jenner
Journal:  J Neurochem       Date:  2001-08       Impact factor: 5.372

Review 8.  Oxidative stress in Parkinson's disease.

Authors:  Peter Jenner
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

9.  Interference of anaesthetics with radioligand binding in neuroreceptor studies.

Authors:  Betina Elfving; Berith Bjørnholm; Gitte Moos Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-25       Impact factor: 9.236

10.  The effect of etorphine on dopamine and noradrenaline concentrations in different central nervous system structures in the rat.

Authors:  B F Kania
Journal:  Acta Physiol Pol       Date:  1977 Nov-Dec
View more
  7 in total

1.  Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.

Authors:  Mallory J Stenslik; Lisa F Potts; James W H Sonne; Wayne A Cass; Jadwiga Turchan-Cholewo; Francois Pomerleau; Peter Huettl; Yi Ai; Don M Gash; Greg A Gerhardt; Luke H Bradley
Journal:  J Neurosci Methods       Date:  2015-05-18       Impact factor: 2.390

2.  Short- and long-term unilateral 6-hydroxydopamine lesions in rats show different changes in characteristics of spontaneous firing of substantia nigra pars reticulata neurons.

Authors:  Sonja Seeger-Armbruster; Andreas von Ameln-Mayerhofer
Journal:  Exp Brain Res       Date:  2012-10-09       Impact factor: 1.972

3.  Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques.

Authors:  M J Stenslik; A Evans; F Pomerleau; R Weeks; P Huettl; E Foreman; J Turchan-Cholewo; A Andersen; W A Cass; Z Zhang; R C Grondin; D M Gash; G A Gerhardt; L H Bradley
Journal:  J Neurosci Methods       Date:  2018-03-31       Impact factor: 2.390

4.  The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease.

Authors:  Ian F Harrison; Nicholas M Powell; David T Dexter
Journal:  J Neurochem       Date:  2018-11-26       Impact factor: 5.372

5.  Neuronal Entropy Depends on the Level of Alertness in the Parkinsonian Globus Pallidus in vivo.

Authors:  Daniela Sabrina Andres; Daniel Cerquetti; Marcelo Merello; Ruedi Stoop
Journal:  Front Neurol       Date:  2014-06-25       Impact factor: 4.003

6.  Ketamine Does Not Exert Protective Properties on Dopaminergic Neurons in the Lactacystin Mouse Model of Parkinson's Disease.

Authors:  Lauren Deneyer; Ann Massie; Eduard Bentea
Journal:  Front Behav Neurosci       Date:  2018-09-19       Impact factor: 3.558

7.  The translocator protein (TSPO) is prodromal to mitophagy loss in neurotoxicity.

Authors:  Michele Frison; Danilo Faccenda; Rosella Abeti; Manuel Rigon; Daniela Strobbe; Britannie S England-Rendon; Diana Cash; Katy Barnes; Mona Sadeghian; Marija Sajic; Lisa A Wells; Dong Xia; Paola Giunti; Kenneth Smith; Heather Mortiboys; Federico E Turkheimer; Michelangelo Campanella
Journal:  Mol Psychiatry       Date:  2021-03-04       Impact factor: 15.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.